Novel recombinant tryptophan mutants of influenza
AssigneeMed Immune Vaccines, Inc.
InventorNeil T. Parkin
Life of this patent
Estimating the term…
Abstract
Recombinant PB2 tryptophan variant influenza viruses, RNA, cDNA and vectors are provided. Also provided are immunogenic compositions containing the variant viruses, methods of producing such viruses and methods for the prophylactic treatment of influenza in humans.
Claims25
A recombinant influenza virus in which the amino acid sequence comprising the PB2 protein has been modified by the substitution of at least one non-native amino acid for at least one native amino acid that affects the cap-binding activity of PB2.
A recombinant influenza A virus in which the amino acid sequence comprising the PB2 has been modified by the substitution of non-native amino acids for the native amino acids at positions 552, 557 and 564.
A recombinant influenza A virus in which the amino acid sequence comprising the PB2 has been modified by the substitution of non-native amino acids for the native amino acids at positions 65, 112, 265, 552, 557 and 564.
An influenza A PB2 protein in which at least one native tryptophan residue at position 552, 557 or 564 is replaced with a non-native amino acid residue.
An influenza A PB2 protein in which the native tryptophan residues at positions 552, 557 and 564 are replaced with non-native amino acid residues.
An influenza A PB2 protein in which the native amino acid residues at positions 65, 112, 265, 552, 557 and 564 are replaced with non-native amino acid residues.
Dependencies are inferred from the claim text.